192 related articles for article (PubMed ID: 33125664)
1. Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET).
Bahri P; Morales DR; Inoubli A; Dogné JM; Straus SMJM
Drug Saf; 2021 Feb; 44(2):193-209. PubMed ID: 33125664
[TBL] [Abstract][Full Text] [Related]
2. Comment on: "Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET)".
Braillon A; Martin M
Drug Saf; 2021 Sep; 44(9):1007-1009. PubMed ID: 34324173
[No Abstract] [Full Text] [Related]
3. Authors' Reply to Braillon and Martin's Comment on "Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET)".
Bahri P; Morales DR; Inoubli A; Dogné JM; Straus SMJM
Drug Saf; 2021 Sep; 44(9):1011-1013. PubMed ID: 34324172
[No Abstract] [Full Text] [Related]
4. Systematising Pharmacovigilance Engagement of Patients, Healthcare Professionals and Regulators: A Practical Decision Guide Derived from the International Risk Governance Framework for Engagement Events and Discourse.
Bahri P; Pariente A
Drug Saf; 2021 Nov; 44(11):1193-1208. PubMed ID: 34528215
[TBL] [Abstract][Full Text] [Related]
5. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing the implementation of medicine risk communications by healthcare professionals in clinical practice: A systematic review.
Alharbi AB; Berrou I; Umaru N; Al Hamid A; Shebl NA
Res Social Adm Pharm; 2023 Jan; 19(1):28-56. PubMed ID: 35989221
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Risk Minimization Measures to Prevent Pregnancy Exposure to Mycophenolate-Containing Medicines in Europe.
Madison T; Donner B; Mutter R; Mingrino R; Alvaro G
Pharmaceut Med; 2019 Oct; 33(5):395-406. PubMed ID: 31933233
[TBL] [Abstract][Full Text] [Related]
8. What do stakeholders expect from patient engagement: Are these expectations being met?
Boudes M; Robinson P; Bertelsen N; Brooke N; Hoos A; Boutin M; Geissler J; Sargeant I
Health Expect; 2018 Dec; 21(6):1035-1045. PubMed ID: 29858529
[TBL] [Abstract][Full Text] [Related]
9. [Risk minimalisation measures for medications; are they incorporated in Dutch clinical guidelines?].
Grupstra RJ; Siiskonen SJ; Gardarsdottir H
Ned Tijdschr Geneeskd; 2024 Jun; 168():. PubMed ID: 38888389
[TBL] [Abstract][Full Text] [Related]
10. Review of Studies Evaluating Effectiveness of Risk Minimization Measures Assessed by the European Medicines Agency Between 2016 and 2021.
Grupstra RJ; Goedecke T; Scheffers J; Strassmann V; Gardarsdottir H
Clin Pharmacol Ther; 2023 Dec; 114(6):1285-1292. PubMed ID: 37634124
[TBL] [Abstract][Full Text] [Related]
11. Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns.
Holm JEJ; Ruppert JG; Ramsden SD
Pharmaceut Med; 2022 Feb; 36(1):33-46. PubMed ID: 35099785
[TBL] [Abstract][Full Text] [Related]
12. 'Engagement' of patients and healthcare professionals in regulatory pharmacovigilance: establishing a conceptual and methodological framework.
Brown P; Bahri P
Eur J Clin Pharmacol; 2019 Sep; 75(9):1181-1192. PubMed ID: 31240364
[TBL] [Abstract][Full Text] [Related]
13. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
14. Application of discrete choice experiments to enhance stakeholder engagement as a strategy for advancing implementation: a systematic review.
Salloum RG; Shenkman EA; Louviere JJ; Chambers DA
Implement Sci; 2017 Nov; 12(1):140. PubMed ID: 29169397
[TBL] [Abstract][Full Text] [Related]
15. A description of medicines-related safety issues evaluated through a referral procedure at the EU level after 2012.
Farcas A; Balcescu T; Anghel L; Bucsa C; Mogoșan C
Expert Opin Drug Saf; 2020 Jun; 19(6):755-762. PubMed ID: 32186202
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Effectiveness of Additional Risk Minimization Measures for Voriconazole in the EU: Findings and Lessons Learned from a Healthcare Professional Survey.
Lem J; Younus M; Aram JA; Moosavi S; Freivogel K; Lewis A; Sobel RE
Pharmaceut Med; 2019 Apr; 33(2):121-133. PubMed ID: 31933256
[TBL] [Abstract][Full Text] [Related]
17. The ethical challenges and opportunities of implementing engagement strategies in health research.
Salerno J; Coleman KJ; Jones F; Peters ES
Ann Epidemiol; 2021 Jul; 59():37-43. PubMed ID: 33894383
[TBL] [Abstract][Full Text] [Related]
18. Key pharmacovigilance stakeholders' experiences of direct patient reporting of adverse drug reactions and their prospects of future development in the European Union.
Inácio P; Cavaco A; Allan E; Airaksinen M
Public Health; 2018 Feb; 155():119-128. PubMed ID: 29346070
[TBL] [Abstract][Full Text] [Related]
19. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
[TBL] [Abstract][Full Text] [Related]
20. A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee.
Pacurariu AC; Coloma PM; van Haren A; Genov G; Sturkenboom MC; Straus SM
Drug Saf; 2014 Dec; 37(12):1059-66. PubMed ID: 25398646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
